As of May 29, 2025, Millennium Pharmacon International Tbk PT (SDPC.JK) reports a Net Margin of 0.43%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Millennium Pharmacon International Tbk PT's Net Margin
Over recent years, Millennium Pharmacon International Tbk PT's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 0.43% |
| 2023-12-31 | 0.98% |
| 2022-12-31 | 0.76% |
| 2021-12-31 | 0.32% |
| 2020-12-31 | 0.11% |
This slight upward trend highlights how Millennium Pharmacon International Tbk PT manages its overall profitability and cost control over time.
Comparing Millennium Pharmacon International Tbk PT's Net Margin to Peers
To better understand Millennium Pharmacon International Tbk PT's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Millennium Pharmacon International Tbk PT (SDPC.JK) | 0.43% |
| Mahavir Advanced Remedies Ltd (531689.BO) | 43.03% |
| Wonik Co Ltd (032940.KQ) | 15.24% |
| Quantum Health Group Ltd (QTM.AX) | 12.25% |
| Business Alignment PCL (BIZ.BK) | 11.91% |
| Shanghai Pioneer Holding Ltd (1345.HK) | 9.90% |
Compared to its competitors, Millennium Pharmacon International Tbk PT's Net Margin is about average compared to peers, reflecting typical industry profitability.